Cancer and a host of other diseases manifest on a molecular level through specific biomarkers, including proteins, nucleic acids such as DNA or RNA, and various other molecular entities. The challenge with these biomarkers lies in their infinitesimal concentrations during the disease’s nascent phase, often evading detection by existing diagnostic tools. Addressing this, the newly developed sensor harnesses a multi-disciplinary approach merging nanotechnology, gene editing, and nonlinear optics to amplify detection capabilities without relying on molecular amplification methods traditionally used in biomarker assays.

At the heart of this sensor is the phenomenon known as second harmonic generation (SHG), a nonlinear optical process wherein incident photons interacting with certain materials are effectively converted into photons of twice the energy — or half the wavelength. The sensor employs molybdenum disulfide (MoS₂), a two-dimensional semiconductor distinguished by its robust SHG response. By leveraging the MoS₂’s properties, the device creates a platform where subtle biochemical interactions translate directly into measurable optical signals, circumventing common issues with background noise that plague many light-based assays.

To precisely modulate the interaction distance essential for enhancing SHG signals, the team implemented DNA tetrahedrons as nanoscopic scaffolds. These tetrahedral structures are meticulously self-assembled from DNA strands, forming rigid, pyramid-like shapes with nanometer precision. Quantum dots, semiconductor nanoparticles renowned for their size-tunable optical characteristics, were tethered to these DNA frameworks. This arrangement enables fine control over the spatial orientation and proximity of quantum dots relative to the MoS₂ surface, thereby dramatically boosting the local electromagnetic field and, consequently, the SHG intensity.

The sensor’s biomarker specificity and detection mechanism owe much to the integration of CRISPR-Cas12a, a precise gene-editing protein programmed to identify target nucleic acid sequences indicative of disease biomarkers. Upon recognizing its target, Cas12a activates collateral cleavage activity, slicing the DNA strands anchoring the quantum dots. This cleavage disrupts the engineered nanostructure, precipitating a measurable decrease in SHG signal. The direct correlation between the presence of the biomarker and SHG signal modulation endows the sensor with remarkable sensitivity and specificity, enabling detection without the need for traditional amplification methods such as PCR.

This amplification-free detection is a profound leap forward, as conventional biomarker assays often entail time-consuming and costly amplification cycles to elevate the signal beyond detectable thresholds. By contrast, the current technology’s design — combining optical nonlinearity for noise suppression, nanometer-scale engineering for signal enhancement, and molecular precision via CRISPR — fosters rapid and accurate biomarker quantification directly from clinical samples. Such efficiency is poised to redefine the landscape of molecular diagnostics.

In practical application, the team focused on miR-21, a microRNA implicated as a lung cancer biomarker. Initial tests in buffer solutions established baseline sensitivity, followed by validation within human serum extracted from lung cancer patients. The sensor demonstrated exceptional performance, effectively distinguishing the target microRNA from a milieu of structurally similar RNA molecules present in serum, underscoring both its specificity and robustness. This real-world applicability suggests a viable path toward clinical translation.

Beyond lung cancer, the sensor’s modular design and programmable DNA constructs imply versatility across a plethora of diseases and biomarkers. The detection scheme could readily adapt to viruses, bacterial pathogens, and other disease-relevant molecules, unlocking potential applications in infectious disease surveillance, environmental monitoring, and neurodegenerative disease diagnostics, such as Alzheimer’s biomarkers. This universality underscores the sensor’s broad impact potential across multiple domains of healthcare and beyond.

Looking forward, the research team has ambitious plans to transform this laboratory-scale technology into a portable, user-friendly device. Miniaturizing the optical setup and integrating it into a compact form factor could enable bedside or point-of-care testing, expanding accessibility to underserved and remote locations lacking sophisticated laboratory infrastructure. Such advancements would democratize early disease detection, empowering timely interventions and personalized patient management.

The union of DNA nanotechnology, quantum dot-enhanced nonlinear optics, and CRISPR-based molecular recognition represents a triumph of interdisciplinary innovation. This synergy facilitates an elegant sensing architecture that balances speed, precision, and minimal complexity—characteristics critical for next-generation diagnostic tools. As the technology matures and moves toward commercialization, its capacity to reshape cancer diagnostics and monitoring stands to significantly impact patient outcomes and healthcare economics.

Published in the journal Optica, under the title “Sub-Attomolar-Level Biosensing of Cancer Biomarkers Using SHG Modulation in DNA Programmable Quantum Dots/MoS₂ Disordered Metasurfaces,” this research marks a seminal contribution to the field of biomedical optics. The detailed mechanisms and experimental validations outlined exemplify how fundamental physics and molecular biology can converge to create disruptive technologies in medicine.

In summary, the development of this highly sensitive SHG-based biosensor integrates the nanoprecision of DNA assembly, the optical enhancement of quantum dots, and the molecular specificity of CRISPR-Cas12a. This marriage of techniques enables the amplification-free detection of cancer biomarkers at previously unattainable sensitivity levels, bringing the prospect of rapid, accurate, and non-invasive cancer detection closer to reality. As such, it holds tremendous promise for revolutionizing how clinicians detect and monitor diseases, ultimately facilitating earlier interventions and improving survival outcomes worldwide.

Subject of Research: Cancer biomarker detection using light-based sensing technologies.

Article Title: Sub-Attomolar-Level Biosensing of Cancer Biomarkers Using SHG Modulation in DNA Programmable Quantum Dots/MoS₂ Disordered Metasurfaces

Web References:

• DOI Link
• Optica Journal Homepage

References:
B. Du, X. Tian, S. Han, Y. Liu, Z. Chen, Y. Liu, L. Li, Z. Xie, L. Gao, K. Jiang, Q. Jiang, S. Chen, H. Zhang, “Sub-Attomolar-Level Biosensing of Cancer Biomarkers Using SHG Modulation in DNA Programmable Quantum Dots/MoS₂ Disordered Metasurfaces” Optica, 13 (2025).

Image Credits: Han Zhang, Shenzhen University

Keywords: Cancer research, Quantum dots, Metasurfaces, Clinical medicine

Focusing on the recent rise of antimicrobial resistance, senior author Andreas Güntner, an expert in mechanical and process engineering, highlighted a significant challenge in modern medicine—namely, the absence of swift diagnostic techniques. Traditionally, diagnosing bacterial infections often involves time-consuming laboratory procedures, with results that can take hours, days, or even weeks. Güntner and his colleagues propose a transformative solution: a straightforward test capable of delivering results in mere seconds to minutes, thereby streamlining the diagnostic process significantly.

Historically, medical practitioners have utilized their olfactory senses to diagnose bacterial infections, relying on specific odors associated with different pathogens. For instance, infections caused by Pseudomonas aeruginosa emit a fragrance reminiscent of sweet grapes, while those resulting from Clostridium bacteria are characterized by a repugnant, foul smell. These distinct olfactory signatures arise from volatile organic compounds (VOCs) released by these microbes, which can also serve as unique biomarkers for detection purposes.

Rather than relying on human olfaction, the research team envisions deploying advanced chemical sensors designed to detect these bacteria-associated VOCs in various bodily fluids, including blood, urine, feces, and sputum. These sensors would operate similarly to existing technologies used in breathalyzers and air-quality monitors, functionally enabling rapid identification of bacterial infections without the need for extensive laboratory procedures.

In their pioneering research, Güntner noted that they had previously commercialized technology for detecting contaminants like methanol in alcoholic beverages. This experience provides them with a solid foundation for transferring this concept into more intricate medical applications, such as the precise identification of the VOC signatures related to infections that may be resistant to antibiotics. This endeavor is particularly crucial in the age of rising antibiotic resistance, positing the potential to directly address this public health crisis.

A key component of the researchers’ strategy lies in understanding the variability of bacterial strains, which can emit diverse combinations and concentrations of VOCs even within the same species. This variance underscores the sensors’ potential to identify infections caused by antimicrobial-resistant strains. An exploration of prior studies demonstrates that these VOC signatures can differentiate between methicillin-resistant Staphylococcus aureus (MRSA) and non-resistant strains, corroborating the feasibility of this technology. However, realizing clinical-grade sensors capable of reliable performance will necessitate further research and development.

One hurdle that must be overcome relates to the minuscule concentrations of VOCs emitted by bacteria, which pose a challenge to the effective design and deployment of suitable sensors. To illustrate this point, Güntner compared the task to searching for a single red ball in a vast room filled with one billion blue balls. The ability to quickly identify and distinguish minor variations in the presence of different bacterial types requires sophisticated detection methodologies where time is of the essence.

Given that bacteria emit a vast array of VOCs, researchers will need to develop sensors with a multifaceted approach, employing different materials and binding capacities to accurately capture and analyze these emissions. Potential materials for these sensors could include metal oxides, polymers, graphene derivatives, and carbon nanotubes, enabling them to leverage cutting-edge advancements in nano-engineering and molecular-scale technologies. To streamline detection and enhance diagnostic accuracy, it would also be essential to equip these devices with advanced filters that can eliminate misleading compounds, such as VOCs produced by human cells or common gaseous byproducts released by various bacteria.

Another crucial aspect of this innovative design involves machine learning algorithms that will play an indispensable role in optimizing sensor functionality. These algorithms will facilitate the identification of the most relevant combinations of VOCs necessary for differentiating between various bacterial types and provide insights into antimicrobial resistance and virulence factors. By harnessing the capabilities of machine learning, the research team aims to refine sensor performance, helping to advance medical diagnostics into a realm that could significantly improve patient care.

Once fully developed, these sensors would provide clinicians with a rapid, user-friendly means of diagnosing bacterial infections with minimal training. The overarching ambition behind this technology is not only to incorporate scientific advancements in VOC analysis into dependable tools but also to ensure that such tools are accessible for everyday use in medical settings. Ultimately, this innovation seeks to enhance patient outcomes and support critical antibiotic stewardship programs, making strides against one of the most pressing challenges in modern medicine.

The pursuit of developing such innovative diagnostic tools emerges at a time when the threat of antimicrobial resistance is escalating. Enhanced diagnostic capabilities could shift clinical paradigms, leading to more tailored treatment interventions and a reduction in the overutilization of broad-spectrum antibiotics. By enabling healthcare professionals to accurately identify specific infections and comprehend their resistance profiles, this technology can contribute to concerted efforts aimed at reducing the prevalence of antibiotic resistance.

In conclusion, the integration of advanced VOC sensors into medical diagnostics presents a potentially paradigm-shifting approach to antibiotic-resistant bacterial infections. By addressing the current limitations of laboratory analysis and utilizing modern engineering and machine learning techniques, researchers are poised to create a more efficient framework for infection diagnosis. Such developments hold promise not only for improving patient care but also for shaping the future landscape of antimicrobial resistance management in a global context.

Subject of Research: Bacterial infections and antimicrobial resistance diagnostics using chemical sensors
Article Title: Microbial and antimicrobial resistance diagnostics by gas sensors and machine learning
News Publication Date: 2-Jul-2025
Web References: Cell Biomaterials
References: DOI 10.1016/j.celbio.2025.100125
Image Credits: Cell Press

Keywords

Antimicrobial resistance, bacterial infections, diagnostics, VOCs, machine learning, chemical sensors, healthcare innovation, patient outcomes, antibiotic stewardship.